ArticleRSC medicinal chemistry2023
Exploration of tricyclic heterocycles as core structures for RIOK2 inhibitors.
Huilan Xiong, Qiuchun Yu, Haowen Ma, Xiuwen Yu, Yifan Ouyang, Zhi-Min Zhang, Wei Zhou, Zhang Zhang, Qian Cai
Open access · greenAbstract read
In one paragraphArticle in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors at 1 institution in 1 country.
Huilan XiongInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Qiuchun YuInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Haowen MaInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Xiuwen YuInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Yifan OuyangInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Zhi-Min ZhangInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Wei ZhouInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.ORCID https://orcid.org/0000-0003-2787-5045 Zhang ZhangInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.
Qian CaiInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People's Republic of China, College of Pharmacy, Jinan University 601 Huangpu Avenue West Guangzhou 510632 China weizhou088@jnu.edu.cn zhang_zhang@jnu.edu.cn caiqian@jnu.edu.cn.ORCID https://orcid.org/0000-0002-5700-3275 Jinan University · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Right open reading frame kinase 2 (RIOK2) is an atypical kinase and has been proved to be involved in multiple human cancers including non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), glioblastoma and anemia. Although tremendous efforts have been devoted to the studies of RIOK2, its biological functions remain poorly understood. It is highly important to develop potent and selective RIOK2 inhibitors as potential research tools to elucidate its functions and as drug candidates for further therapies. We have previously identified a highly potent and selective RIOK2 inhibitor (
Identifiers
PMID37859717
PMCPMC10583808
OpenAlexW4385154011
What OpenQuestion holds
Textmetadata
Read underepoch 390